» Articles » PMID: 23751858

Wide Spectrum of Clinical Manifestations in Children with Tuberous Sclerosis Complex--follow-up of 20 Children

Overview
Journal Brain Dev
Publisher Elsevier
Specialty Neurology
Date 2013 Jun 12
PMID 23751858
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: TSC is a multisystem genetic disorder predisposing to multiple organ manifestations and developmental problems. Clinical follow-up of patients remains a challenge for the caring paediatrician.

Methods: We performed a retrospective analysis of clinical manifestations, diagnostic and therapeutic data in 20 children with the diagnosis of tuberous sclerosis complex (TSC) to answer the following questions: are the clinical guidelines and imaging strategies appropriate to discover complications, are there significant early predictors of long-term prognosis, what is the age range for signs and symptoms to occur.

Results: Cardiac rhabdomyoma were present in 18 children and occurred as earliest manifestation. 8 of these exhibited associated arrhythmia or congenital cardiac anomalies. Seizures combined with cortical tubers and subependymal nodules occurred in 18 patients and were most likely to start in infancy, which was associated with later cognitive impairment. Cutaneous manifestations (15 children) occurred in late childhood and school age, whilst renal angiomyolipomas (11) developed in puberty.

Discussion: The clinical course and imaging strategies are compared with data from previous studies. A review of TSC in regard to the multiple manifestations is provided.

Citing Articles

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical....

Driedger J, Schroter J, Syrbe S, Saffari A Orphanet J Rare Dis. 2025; 20(1):2.

PMID: 39762914 PMC: 11702139. DOI: 10.1186/s13023-024-03495-1.


Exploring Cardiovascular Involvement in Tuberous Sclerosis: Insights for Pediatric Clinicians.

Lazea C, Taranu I, Bolboaca S Children (Basel). 2024; 11(6).

PMID: 38929253 PMC: 11201926. DOI: 10.3390/children11060674.


Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group.

Mekahli D, Muller R, Marlais M, Wlodkowski T, Haeberle S, de Argumedo M Nat Rev Nephrol. 2024; 20(6):402-420.

PMID: 38443710 DOI: 10.1038/s41581-024-00818-0.


Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

Saffari A, Brosse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A Orphanet J Rare Dis. 2019; 14(1):96.

PMID: 31053163 PMC: 6500021. DOI: 10.1186/s13023-019-1077-6.


Comparison of Color Fundus Photography, Infrared Fundus Photography, and Optical Coherence Tomography in Detecting Retinal Hamartoma in Patients with Tuberous Sclerosis Complex.

Bai D, Wang X, Zhao J, Li L, Gao J, Wang N Chin Med J (Engl). 2016; 129(10):1229-35.

PMID: 27174333 PMC: 4878170. DOI: 10.4103/0366-6999.181976.